Cancer Research SABCS Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanner, M.
Right arrow Articles by Isola, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanner, M.
Right arrow Articles by Isola, J.
[Cancer Research 61, 5345-5348, July 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Amplification of HER-2/neu and Topoisomerase II{alpha} in Primary and Metastatic Breast Cancer1

Minna Tanner, Päivi Järvinen and Jorma Isola2

Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University and Tampere University Hospital, FIN-33014 Tampere, Finland

Amplification of the HER-2/neu oncogene and amplification of the topoisomerase II{alpha} gene are important determinators of the response to chemotherapy in advanced breast cancer. Assays of these genes are usually carried out using primary tumor samples, because biopsies from metastatic lesions are not usually taken. We studied the concordance of Her-2/neu and topoisomerase II{alpha} amplification in primary breast tumors and their metastases by immunostaining and DNA in situ hybridization. HER-2/neu amplification, present in 28% of the primary tumors (n = 46), was always associated with amplification in its metastasis. Conversely, no metastases with HER-2/neu amplification were seen without amplification in the primary tumor. Topoisomerase II{alpha} gene copy status (amplification/deletion/unaltered) remained generally unchanged in HER-2/neu-positive tumors, but in three cases, the predominant cell population in metastatic tissue was present only as a subpopulation in the primary tumor. We conclude that amplification of HER-2/neu measured in primary tumor reflects the status of metastases. Minor discrepancies between primary and metastatic tumors in topoisomerase II{alpha} gene copy status may reflect evolvement of the amplicon structure in successive cell divisions.




This article has been cited by other articles:


Home page
 Ann OncolHome page
S.J. Aitken, J.S. Thomas, S.P. Langdon, D.J. Harrison, and D. Faratian
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases
Ann. Onc., November 3, 2009; (2009) mdp427v3.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
C. G. Cronin, T. Cashell, J. N. Mhuircheartaigh, R. Swords, M. Murray, G. J. O'Sullivan, and D. O'Keeffe
Bone Biopsy of New Suspicious Bone Lesions in Patients With Primary Carcinoma: Prevalence and Probability of an Alternative Diagnosis
Am. J. Roentgenol., November 1, 2009; 193(5): W407 - W410.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
F. Penault-Llorca, M. Bilous, M. Dowsett, W. Hanna, R. Y. Osamura, J. Ruschoff, and M. van de Vijver
Emerging Technologies for Assessing HER2 Amplification
Am J Clin Pathol, October 1, 2009; 132(4): 539 - 548.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bergh
Quo Vadis With Targeted Drugs in the 21st Century?
J. Clin. Oncol., January 1, 2009; 27(1): 2 - 5.
[Full Text] [PDF]

Home page
 JCOHome page
J. M.S. Bartlett, A. Munro, D. A. Cameron, J. Thomas, R. Prescott, and C. J. Twelves
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
J. Clin. Oncol., November 1, 2008; 26(31): 5027 - 5035.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Guarneri, S. Giovannelli, G. Ficarra, S. Bettelli, A. Maiorana, F. Piacentini, E. Barbieri, M. V. Dieci, R. D'Amico, G. Jovic, et al.
Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management
Oncologist, August 1, 2008; 13(8): 838 - 844.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
M. Campos, C. Prior, F. Warleta, I. Zudaire, J. Ruiz-Mora, R. Catena, A. Calvo, and J. J. Gaforio
Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques
J. Histochem. Cytochem., July 1, 2008; 56(7): 667 - 675.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al.
Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. S. Knoop, H. Knudsen, E. Balslev, B. B. Rasmussen, J. Overgaard, K. V. Nielsen, A. Schonau, K. Gunnarsdottir, K. E. Olsen, H. Mouridsen, et al.
Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
J. Clin. Oncol., October 20, 2005; 23(30): 7483 - 7490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Isola, M. Tanner, A. Forsyth, T. G. Cooke, A. D. Watters, and J. M. S. Bartlett
Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization
Clin. Cancer Res., July 15, 2004; 10(14): 4793 - 4798.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Meng, D. Tripathy, S. Shete, R. Ashfaq, B. Haley, S. Perkins, P. Beitsch, A. Khan, D. Euhus, C. Osborne, et al.
HER-2 gene amplification can be acquired as breast cancer progresses
PNAS, June 22, 2004; 101(25): 9393 - 9398.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-L. Erkinheimo, H. Lassus, P. Finne, B. P. van Rees, A. Leminen, O. Ylikorkala, C. Haglund, R. Butzow, and A. Ristimaki
Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma
Clin. Cancer Res., January 15, 2004; 10(2): 538 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius
Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients
Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Staff, J. Isola, and M. Tanner
Haplo-insufficiency of BRCA1 in Sporadic Breast Cancer
Cancer Res., August 15, 2003; 63(16): 4978 - 4983.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Oncologist, August 1, 2003; 8(4): 307 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Leyland-Jones
Trastuzumab therapy for the metastatic patient: does the primary match?
Ann. Onc., July 1, 2002; 13(7): 993 - 994.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D. Gancberg, A. Di Leo, F. Cardoso, G. Rouas, M. Pedrocchi, M. Paesmans, A. Verhest, C. Bernard-Marty, M. J. Piccart, and D. Larsimont
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Ann. Onc., July 1, 2002; 13(7): 1036 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. A. Iacobuzio-Donahue, A. Maitra, G. L. Shen-Ong, T. van Heek, R. Ashfaq, R. Meyer, K. Walter, K. Berg, M. A. Hollingsworth, J. L. Cameron, et al.
Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology
Am. J. Pathol., April 1, 2002; 160(4): 1239 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ristimaki, A. Sivula, J. Lundin, M. Lundin, T. Salminen, C. Haglund, H. Joensuu, and J. Isola
Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer
Cancer Res., February 1, 2002; 62(3): 632 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. J. Savinainen, O. R. Saramaki, M. J. Linja, O. Bratt, T. L. J. Tammela, J. J. Isola, and T. Visakorpi
Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer
Am. J. Pathol., January 1, 2002; 160(1): 339 - 345.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.